An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial

Oncology

Volumn 69, Issue 4, 2005, Pages 283-289

  Ferrari, Vittorio ^a   Valcamonico, Francesca ^a,b   Amoroso, Vito ^a   Simoncini, Edda ^a   Vassalli, Lucia ^a   Marpicati, Patrizia ^a   Rangoni, Giovanni ^a   Grisanti, Salvatore ^a   Pasinetti, Nadia ^a   Marini, Giovanni ^a  

^a Beretta Foundation   (Italy)

^b UO Oncologia Medica   (Italy)

Author keywords

Advanced colorectal cancer; Alternating regimen; Phase II trial; Triple combination chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; VOMITING;

EID: 28644451453     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089677     Document Type: Article

References (34)

1. Black RJ, Bray F, Ferlay J, et al: Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-1107.
2. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-S66.
3. The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
4. Kohne CH, Schoffski P, Wilke H, et al: Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
5. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
6. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;14:808-815.
7. Rivory LP, Riou JF, Haaz MC, et al: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996;56:3689-3694.
8. Pommier Y, Tanizawa A, Kohn KW: Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 1994;29B:73-92.
9. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
10. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000;355:1041-1047.
11. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitior SN-38 and the diamino-cyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999;5:1189-1196.
12. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;181:136-147.
13. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
14. Fischel JL, Rostagno P, Formento P, et al: Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 2001;84:579-585.
15. Souglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002;20:2651-2657.
16. Becouarn Y, Gamelin E, Coudert B, et al: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pre-treated metastatic colorectal cancer patients. J Clin Oncol 2001;19:4195-4201.
17. Rubio G, Chacon M, Coppola F, et al: CPT-11/oxaliplatin (OXA) plus folinic acid (FA)/5-FU bolus (triple combination): An active and feasible combination in metastatic colorectal cancer (CRC) patients (pts) (abstract No 2254). Proc Am Soc Clin Oncol 2002;21:110b.
18. Roth AD, Seium Y, Ruhstaller T, et al: Oxaliplatin (OXA) combined with irinotecan (CPT-11) and 5-FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study (abstract No 570). Proc Am Soc Clin Oncol 2002;21:143a.
19. Goetz MP, Erlichman C, Windebank AJ, et al: Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003;20:3761-3769.
20. Calvo E, Gonzales-Cao M, Cortes J, et al: Combined irinotecan, oxaliplatin, 5-FU in patients (Pts) with metastatic colorectal cancer (MCC) (abstract No 1008). Proc Am Soc Clin Oncol 2000;19:259a.
21. Ychou M, Conroy T, Seitz JF, et al: An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every two weeks in patients with advanced solid tumors. Ann Oncol 2003;14:481-489.
22. Falcone A, Masi G, Allegrini G, et al: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;19:4006-4014.
23. Gil-Delgado M, Bastian G, Guinet F, et al: Final results of oxaliplatin (LOHP) + irinotecan (CPT-11) and FU-FOL (LV5FU2) combination and pharmacokinetic (PK) analysis in advanced colorectal cancer (ACRC) patients (Pt) (abstract No 558). Proc Am Soc Clin Oncol 2001;20:140a.
24. Goldie JH, Coldman AJ: Mathematical model for relating sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
26. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
27. Cox DR: The Analysis of Binary Data. London, Methuen, 1970.
28. Goldberg RM, Sargent DJ, Mortem RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
29. Tournigand C, Louvet C, Quinax E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study (abstract). Proc Am Soc Clin Oncol 2001;20:124.
30. Grem JL, Quinn M, Ismail AS, et al: Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemother Pharmacol 2001;47:117-125.
31. Jakobsen A, Berglund A, Glimelius B, et al: Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002;41:525-531.
32. Glimelius B, Jakobsen A, Graf W, et al: Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer 1998;34:674-678.
33. Ramanathan RK, Clark JW, Kemeny NE, et al: Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003;21:2904-2911.
34. Kohne CH: Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001;12:435-442.